CN
News & Events
Investor’s Experience Sharing Forum: Discussion on the Pharmaceutical Investment Trends and Development Opportunities under New Circumstances
News & Events CBIIC 2023.09.29 222

2-1.jpg

On September 26, Investors’ Experience Forum, hosted by PhIRDA Pharmaceutical Innovation Investment Specialty Committee and supported by LYZZ capital, was held on the 8th China BioMed Innovation and Investment Conference (CBIIC). Investors, professionals, and experts in the pharmaceutical sector gathered to discuss the financing, investment, management and withdrawal in the global pharmaceutical industry in the new circle, contributing wisdom to capital-enabled pharmaceutical innovation.

2-2.jpg

Chair Li Kaijun, Vice-Chairman of the PhIRDA Pharmaceutical Innovation Investment Specialty Committee, and Managing Partner of LYZZ Capital

Li Qian, president of Finance SBU of Healthcare, Culture & Tourism, PingAn Bank addressed a keynote speech of On the Pulse of Time, on the Side of Clients.

2-3.jpg

Li Qian

Estelle Xu, corporate strategy CoE, senior principal at IQVIA, addressed a keynote speech entitled Innovation Reshaping under the New Environment, from Global to China.

2-4.jpg

Estelle Xu

Xu Jun, managing director and head of strategic equity investment department, Taikang Asset Management Co., Ltd. addressed a keynote speech entitled Move the Mountain Reflection upon Healthcare Service Investment.

2-5.jpg

Xu Jun

Following the keynote speeches, the Panel of Challenges and Development Opportunities for China’s Innovative Pharmaceutical Industry unfolded. The moderator is Kevin Xu, managing director, head of Asia healthcare and life science investing, Goldman Sachs Asset Management. Kevin Li, Yuan Jianwei, partner of Vertex Ventures China, Lily Zhang, founding partner, TTM Capital, and Pan Xiaogang, managing director, AZ-CICC Healthcare Investment Fund participated in the panel discussion. They reached a consensus that since 2015, thanks to the national policies encouraging innovation and its integration into the capital markets, China’s pharmaceutical industry has developed rapidly. Now, facing the downturn of the industry, R&D of innovative drugs need to focus on clinical needs; more importantly, it should satisfy the diversified market needs.

2-6.jpg

Kevin Xu, Yuan Jianwei, Li Kaijun, Lily Zhang, Pan Xiaogang (From Left to Right)

The Panel of Exploration and Thoughts of Medical Investment under the New Circumstances unfolded with Bryan Sun as the moderator. Lynn Yang, partner of Sequoia China, Chen Miao, partner of Huatai Investment, Leo Shi, managing director of Warburg Pincus, and Richard Lu, managing director of China Life Private Equity Investment Company Limited, participated in the panel. They reached a consensus that, due to policies and complex international landscapes, investment in healthcare industry faces both opportunities and challenges. In the industry and capital winter, we need to accelerate cooperation and work jointly to go through the adjustment period.

2-7.jpg

Bryan Sun, Lynn Yang, Leo Shi, Chen Miao, and Richard Lu (From Left to Right)

Investor’s Experience Sharing Forum concluded at the support of guests attending. Experts from investment circle and legal circle engaged in in-depth discussion about popular issues in the pharmaceutical field, shared their experience and insights, inspiring participants.

2-8.jpg

Forum